Sandoz has signed a direct manufacturing and supply agreement with the government of Rwanda to promote the stable provision ...

The agreement with the Rwandan government, which initially covers about 60 products, is a first step toward a sustainable ...

Ever wondered if Sandoz Group stock could be a hidden value play, or if you're just jumping in after the most exciting moves? Let's find out what might actually be under the hood. After a rocky 2.4% ...

Sandoz is doubling down on its commitment to Slovenia in its globe-trotting biosimilar growth quest. The Novartis generics unit is plugging $90 million into a new biosimilar technical development ...

Sandoz discusses PBMs, generics and the 340B drug pricing program in its new report titled, Solving American’s Drug Shortage Dilemma, For Good. Noting that despite successes and benefits, the modern U ...

Sandoz bought the Cimerli (ranibizumab-eqrn) business from Coherus Biosciences, the companies announced Monday morning. In January, Sandoz and Coherus entered into an agreement on a $170 million cash ...

Right on the heels of Pfizer’s Accuretic recall, nitrosamine impurities have forced another major drugmaker to pull certain meds from U.S. shelves. Novartis’ Sandoz is recalling 13 lots of oral ...

At an Extraordinary General Meeting, Novartis AG's (NYSE:NVS) shareholders approved the proposed 100% spin-off of Sandoz. Novartis shareholders and Novartis ADR holders will receive one Sandoz share ...

(Reuters) -Sandoz shares dipped on their market debut on Wednesday after the generic and biosimilar drugmaker was valued at a lower-than-expected 10.3 billion Swiss francs ($11.2 billion) in its ...